vs
NEXTNRG, INC.（NXXT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是NEXTNRG, INC.的1.3倍（$30.3M vs $23.0M），NEXTNRG, INC.净利率更高（-116.1% vs -221.3%，领先105.2%），NEXTNRG, INC.同比增速更快（238.9% vs 43.0%），过去两年NEXTNRG, INC.的营收复合增速更高（86.8% vs 39.4%）
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NXXT vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.0M
营收增速更快
NXXT
高出195.9%
43.0%
净利率更高
NXXT
高出105.2%
-221.3%
两年增速更快
NXXT
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.0M | $30.3M |
| 净利润 | $-26.7M | $-67.1M |
| 毛利率 | 10.3% | — |
| 营业利润率 | -107.2% | -190.0% |
| 净利率 | -116.1% | -221.3% |
| 营收同比 | 238.9% | 43.0% |
| 净利润同比 | -974.9% | -31.2% |
| 每股收益（稀释后） | $1.30 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NXXTRGNX
| Q4 25 | $23.0M | $30.3M | ||
| Q3 25 | $22.9M | $29.7M | ||
| Q2 25 | $19.7M | $21.4M | ||
| Q1 25 | $16.3M | $89.0M | ||
| Q4 24 | $6.8M | $21.2M | ||
| Q3 24 | $7.0M | $24.2M | ||
| Q2 24 | $7.4M | $22.3M | ||
| Q1 24 | $6.6M | $15.6M |
净利润NXXTRGNX
| Q4 25 | $-26.7M | $-67.1M | ||
| Q3 25 | $-14.1M | $-61.9M | ||
| Q2 25 | $-36.1M | $-70.9M | ||
| Q1 25 | $-8.8M | $6.1M | ||
| Q4 24 | $-2.5M | $-51.2M | ||
| Q3 24 | $-10.6M | $-59.6M | ||
| Q2 24 | $-5.6M | $-53.0M | ||
| Q1 24 | $-2.7M | $-63.3M |
毛利率NXXTRGNX
| Q4 25 | 10.3% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 8.0% | — | ||
| Q1 25 | 3.2% | — | ||
| Q4 24 | 2.5% | 70.2% | ||
| Q3 24 | 8.7% | 48.8% | ||
| Q2 24 | 7.4% | 52.5% | ||
| Q1 24 | 7.0% | 72.6% |
营业利润率NXXTRGNX
| Q4 25 | -107.2% | -190.0% | ||
| Q3 25 | -39.4% | -176.3% | ||
| Q2 25 | -156.2% | -296.3% | ||
| Q1 25 | -35.4% | 13.6% | ||
| Q4 24 | -62.8% | -242.1% | ||
| Q3 24 | -42.7% | -256.6% | ||
| Q2 24 | -35.2% | -251.3% | ||
| Q1 24 | -28.2% | -408.8% |
净利率NXXTRGNX
| Q4 25 | -116.1% | -221.3% | ||
| Q3 25 | -61.8% | -208.3% | ||
| Q2 25 | -183.3% | -331.8% | ||
| Q1 25 | -54.0% | 6.8% | ||
| Q4 24 | -36.6% | -241.3% | ||
| Q3 24 | -152.0% | -246.3% | ||
| Q2 24 | -76.0% | -237.7% | ||
| Q1 24 | -40.6% | -405.4% |
每股收益（稀释后）NXXTRGNX
| Q4 25 | $1.30 | $-1.30 | ||
| Q3 25 | $-0.12 | $-1.20 | ||
| Q2 25 | $-0.30 | $-1.38 | ||
| Q1 25 | $-1.60 | $0.12 | ||
| Q4 24 | $-3.72 | $-0.99 | ||
| Q3 24 | $-0.71 | $-1.17 | ||
| Q2 24 | $-0.06 | $-1.05 | ||
| Q1 24 | $-1.48 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-19.7M | $102.7M |
| 总资产 | $11.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NXXTRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | $306.8K | $290.4M | ||
| Q1 24 | $48.6K | $338.7M |
总债务NXXTRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $9.2M | — | ||
| Q3 24 | $725.3K | — | ||
| Q2 24 | $8.8M | — | ||
| Q1 24 | $7.3M | — |
股东权益NXXTRGNX
| Q4 25 | $-19.7M | $102.7M | ||
| Q3 25 | $-16.3M | $161.5M | ||
| Q2 25 | $-13.6M | $213.7M | ||
| Q1 25 | $-5.6M | $274.2M | ||
| Q4 24 | $-12.7M | $259.7M | ||
| Q3 24 | $3.6M | $301.4M | ||
| Q2 24 | $-4.8M | $348.3M | ||
| Q1 24 | $-3.3M | $390.7M |
总资产NXXTRGNX
| Q4 25 | $11.1M | $453.0M | ||
| Q3 25 | $19.6M | $525.2M | ||
| Q2 25 | $25.5M | $581.0M | ||
| Q1 25 | $26.0M | $490.9M | ||
| Q4 24 | $22.4M | $466.0M | ||
| Q3 24 | $5.6M | $519.1M | ||
| Q2 24 | $22.4M | $569.4M | ||
| Q1 24 | $5.8M | $629.2M |
负债/权益比NXXTRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-392.6K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NXXTRGNX
| Q4 25 | $-392.6K | $-52.3M | ||
| Q3 25 | $-7.8M | $-56.0M | ||
| Q2 25 | $-564.5K | $-49.3M | ||
| Q1 25 | $-5.8M | $33.6M | ||
| Q4 24 | $-1.6M | $-31.6M | ||
| Q3 24 | $3.6M | $-40.5M | ||
| Q2 24 | $-7.0M | $-45.5M | ||
| Q1 24 | $-1.4M | $-55.5M |
自由现金流NXXTRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率NXXTRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度NXXTRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率NXXTRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NXXT
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
